SCHEMBL15428751

SCHEMBL15428751

Cc1cccc(-n2nccc2N)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
ALDH1A1 P00352 3/20 0.60
KMT2A Q03164 2/20 0.51
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
KDM4E B2RXH2 1/20 0.49
HTT P42858 1/20 0.49
BLM P54132 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.46
NR3C2 P08235 1/20 0.46
KHK P50053 1/20 0.46
PAX8 Q06710 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPK14 Q16539 1/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15428658 0.83 POLB (0.57) POLBALDH1A1KMT2ANPC1RAB9A
SCHEMBL6214118 0.81 ALDH1A1 (0.50) POLBALDH1A1KMT2ANPC1RAB9A
SCHEMBL544605 0.79 POLB (0.58) POLBALDH1A1KMT2ANPC1RAB9A
SCHEMBL544860 0.79 POLB (0.61) POLBALDH1A1KMT2ANPC1RAB9A
SCHEMBL544287 0.79 POLB (0.61) POLBALDH1A1KMT2ANPC1RAB9A
SCHEMBL23399997 0.79 KMT2A (0.48) POLBALDH1A1KMT2ANPC1RAB9A
SCHEMBL15555973 0.79 ALDH1A1 (0.47) POLBALDH1A1KMT2ANPC1RAB9A
SCHEMBL544859 0.79 POLB (0.61) POLBALDH1A1KMT2ANPC1RAB9A
SCHEMBL544667 0.79 POLB (0.61) POLBKMT2ANPC1RAB9ANR3C2
SCHEMBL1012991 0.78 POLB (0.56) POLBALDH1A1KDM4EHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
WO-2017210678-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME An2H Discovery Limited (IE) 2017-12-07 WO disclosed
US-20160244456-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2016-08-25 US disclosed
EP-2962566-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS Genentech, Inc. (US) 2016-01-06 EP disclosed
EP-2348860-B1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH INC (US) 2015-05-27 EP disclosed
US-20140107099-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2014-04-17 US disclosed
US-8637526-B2 Pyrazolopyrimidine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2014-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 IDUA, MAN2B1, GBA1 POLB 2245/4885ALDH1A1 796/4885KMT2A 3761/4885
US-20140107099-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 POLB 2697/4885ALDH1A1 1236/4885KMT2A 1030/4885
US-20160244456-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 POLB 2697/4885ALDH1A1 1236/4885KMT2A 1030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.